C4 Therapeutics Inc
CCCC
查看详细走势图
2.140USD
-0.050-2.28%
收盘 01/09, 16:00（美东）报价延迟15分钟
158.73M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.28%
5天
+10.88%
1月
-17.37%
6月
+5.94%
今年开始到现在
+12.04%
1年
-44.27%
查看详细走势图
TradingKey C4 Therapeutics Inc股票评分
单位: USD 更新时间: 2026-01-09操作建议
C4 Therapeutics Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名70/396位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价11.43。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
C4 Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
C4 Therapeutics Inc亮点
亮点风险
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
业绩增长期
公司处于发展阶段，最新年度总收入35.58M美元
估值合理
公司最新PE估值-1.28，处于3年历史合理位
机构加仓
最新机构持股70.29M股，环比增加2.20%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值191.82K
分析师目标
根据
8
位分析师
买入
评级
11.429
目标均价
+462.98%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
C4 Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
C4 Therapeutics Inc简介
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
公司代码CCCC
公司C4 Therapeutics Inc
CEOHirsch (Andrew J)
网址https://c4therapeutics.com/
常见问题
C4 Therapeutics Inc(CCCC)的当前股价是多少？
C4 Therapeutics Inc(CCCC)的当前股价是 2.140。
C4 Therapeutics Inc的股票代码是什么？
C4 Therapeutics Inc的股票代码是CCCC。
C4 Therapeutics Inc股票的52周最高点是多少？
C4 Therapeutics Inc股票的52周最高点是4.070。
C4 Therapeutics Inc股票的52周最低点是多少？
C4 Therapeutics Inc股票的52周最低点是1.085。
C4 Therapeutics Inc的市值是多少？
C4 Therapeutics Inc的市值是158.73M。
C4 Therapeutics Inc的净利润是多少？
C4 Therapeutics Inc的净利润为-105.32M。
现在C4 Therapeutics Inc(CCCC)的股票是买入、持有还是卖出？
根据分析师评级，C4 Therapeutics Inc(CCCC)的总体评级为买入，目标价格为11.429。
C4 Therapeutics Inc(CCCC)股票的每股收益（EPS TTM）是多少
C4 Therapeutics Inc(CCCC)股票的每股收益（EPS TTM）是-1.675。
相关品种
